Total Payments
$704.05
2023 Payments
$614.06
Companies
22
Transactions
38
Medicare Patients
1,728
Medicare Billing
$280,840
Payment Breakdown by Category
Food & Beverage$692.13 (98.3%)
Education$11.92 (1.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $692.13 | 37 | 98.3% |
| Education | $11.92 | 1 | 1.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Kite Pharma, Inc. | $75.90 | 3 | $0 (2023) |
| Celgene Corporation | $69.00 | 5 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $58.70 | 3 | $0 (2023) |
| Pharmacyclics LLC, An AbbVie Company | $56.13 | 2 | $0 (2023) |
| Regeneron Healthcare Solutions, Inc. | $55.65 | 3 | $0 (2023) |
| Astellas Pharma US Inc | $46.62 | 2 | $0 (2023) |
| Seagen Inc. | $40.78 | 2 | $0 (2023) |
| Merck Sharp & Dohme LLC | $37.66 | 2 | $0 (2023) |
| BeiGene USA, Inc. | $30.81 | 2 | $0 (2023) |
| Mirati Therapeutics, Inc. | $28.64 | 2 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $614.06 | 32 | Kite Pharma, Inc. ($75.90) |
| 2022 | $43.29 | 3 | Daiichi Sankyo Inc. ($15.19) |
| 2021 | $46.70 | 3 | Astellas Pharma US Inc ($23.08) |
All Payment Transactions
38 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/13/2023 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $12.88 | General |
| Category: Hematology | ||||||
| 12/11/2023 | Pharmacyclics LLC, An AbbVie Company | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $33.67 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2023 | Seagen Inc. | TUKYSA (Drug) | Food and Beverage | In-kind items and services | $20.39 | General |
| Category: Oncology | ||||||
| 11/10/2023 | Janssen Biotech, Inc. | — | Food and Beverage | In-kind items and services | $24.07 | General |
| 11/06/2023 | Pharmacyclics LLC, An AbbVie Company | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $22.46 | General |
| Category: ONCOLOGY | ||||||
| 11/03/2023 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $26.34 | General |
| Category: CELLT | ||||||
| 10/09/2023 | AVEO Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $15.91 | General |
| Category: Oncology | ||||||
| 10/05/2023 | Novartis Pharmaceuticals Corporation | TASIGNA (Drug), SCEMBLIX | Food and Beverage | In-kind items and services | $15.75 | General |
| Category: Oncology | ||||||
| 09/21/2023 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $14.45 | General |
| Category: Hematology | ||||||
| 09/11/2023 | ARRAY BIOPHARMA INC | XALKORI (Drug), LORBRENA, BRAFTOVI | Food and Beverage | In-kind items and services | $14.27 | General |
| Category: ONCOLOGY | ||||||
| 09/08/2023 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $14.65 | General |
| Category: Oncology | ||||||
| 09/05/2023 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $14.05 | General |
| Category: Hematology | ||||||
| 08/29/2023 | Seagen Inc. | TUKYSA (Drug) | Food and Beverage | In-kind items and services | $20.39 | General |
| Category: Oncology | ||||||
| 08/21/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $19.66 | General |
| Category: ONCOLOGY | ||||||
| 08/16/2023 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $32.21 | General |
| Category: CELLT | ||||||
| 08/10/2023 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $16.56 | General |
| Category: ONCOLOGY | ||||||
| 07/22/2023 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $21.16 | General |
| Category: ONCOLOGY | ||||||
| 07/20/2023 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | In-kind items and services | $13.88 | General |
| Category: ONCOLOGY | ||||||
| 07/13/2023 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $25.34 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 06/28/2023 | Novartis Pharmaceuticals Corporation | KISQALI (Drug), PIQRAY | Food and Beverage | In-kind items and services | $17.61 | General |
| Category: Oncology | ||||||
| 05/17/2023 | PFIZER INC. | IBRANCE (Drug), COMIRNATY, PAXLOVID | Food and Beverage | In-kind items and services | $17.60 | General |
| Category: ONCOLOGY | ||||||
| 05/13/2023 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $23.54 | General |
| Category: Oncology | ||||||
| 05/08/2023 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $21.49 | General |
| Category: Oncology | ||||||
| 04/27/2023 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $14.77 | General |
| Category: Hematology | ||||||
| 04/25/2023 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | In-kind items and services | $14.76 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 419 | 829 | $209,563 | $71,742 |
| 2022 | 7 | 447 | 805 | $166,990 | $71,389 |
| 2021 | 7 | 437 | 842 | $160,495 | $72,220 |
| 2020 | 7 | 425 | 799 | $136,404 | $65,489 |
Total Patients
1,728
Total Services
3,275
Medicare Billing
$280,840
Procedure Codes
29
All Medicare Procedures & Services
29 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 72 | 222 | $51,060 | $20,338 | 39.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 34 | 172 | $55,268 | $16,862 | 30.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 85 | 100 | $44,500 | $12,999 | 29.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 101 | 169 | $32,042 | $11,527 | 36.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 81 | 116 | $11,728 | $5,044 | 43.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 21 | 21 | $6,670 | $2,168 | 32.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 13 | 13 | $5,736 | $1,822 | 31.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 12 | 16 | $2,560 | $982.08 | 38.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 51 | 186 | $37,010 | $18,497 | 50.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 74 | 188 | $43,240 | $14,928 | 34.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 90 | 97 | $43,165 | $14,927 | 34.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 95 | 161 | $22,085 | $11,860 | 53.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 91 | 127 | $12,325 | $5,910 | 48.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 21 | 21 | $4,725 | $2,865 | 60.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 25 | 25 | $4,440 | $2,402 | 54.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 121 | 261 | $32,914 | $17,910 | 54.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 75 | 205 | $45,566 | $16,542 | 36.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 76 | 89 | $38,604 | $13,868 | 35.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 34 | 120 | $23,340 | $12,631 | 54.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 89 | 125 | $11,215 | $5,850 | 52.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 29 | 29 | $6,471 | $4,008 | 61.9% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 13 | 13 | $2,385 | $1,411 | 59.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 120 | 294 | $31,488 | $16,923 | 53.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 83 | 93 | $38,688 | $14,688 | 38.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 83 | 170 | $35,506 | $14,038 | 39.5% |
About Dr. Getinet Ayalew, M.D
Dr. Getinet Ayalew, M.D is a Hematology & Oncology healthcare provider based in Bridgeton, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/01/2007. The National Provider Identifier (NPI) number assigned to this provider is 1326235797.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Getinet Ayalew, M.D has received a total of $704.05 in payments from pharmaceutical and medical device companies, with $614.06 received in 2023. These payments were reported across 38 transactions from 22 companies. The most common payment nature is "Food and Beverage" ($692.13).
As a Medicare-enrolled provider, Ayalew has provided services to 1,728 Medicare beneficiaries, totaling 3,275 services with total Medicare billing of $280,840. Data is available for 4 years (2020–2023), covering 29 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Bridgeton, MO
- Active Since 10/01/2007
- Last Updated 11/02/2020
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1326235797
Products in Payments
- Yescarta (Drug) $58.55
- EPKINLY (Drug) $56.13
- LIBTAYO (Biological) $55.65
- Pomalyst (Drug) $41.70
- TUKYSA (Drug) $40.78
- KEYTRUDA (Biological) $37.66
- BRUKINSA (Drug) $30.81
- KRAZATI (Drug) $28.64
- LEQVIO (Drug) $25.34
- Orserdu (Drug) $24.91
- Padcev (Drug) $23.54
- PADCEV (Drug) $23.08
- SARCLISA (Biological) $21.49
- JAYPIRCA (Drug) $19.00
- KISQALI (Drug) $17.61
- IBRANCE (Drug) $17.60
- FOTIVDA (Drug) $15.91
- TASIGNA (Drug) $15.75
- ENHERTU (Drug) $15.19
- REBLOZYL (Biological) $14.45
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.